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Low-dose intranasal versus oral midazolam
for routine body MRI of claustrophobic
patients
Abstract The purpose of this
study was to assess prospectively
the potential of low-dose intranasal
midazolam compared to oral
midazolam in claustrophobic patients
undergoing routine body magnetic
resonance imaging (MRI). Seventy-
two adult claustrophobic patients re-
ferred for body MRI were randomly
assigned to one of two treatment
groups (TG1 and TG2). The 36
patients of TG1 received 7.5 mg
midazolam orally 15 min before MRI,
whereas the 36 patients of TG2
received one (or, if necessary, two)
pumps of a midazolam nasal spray
into each nostril immediately prior to
MRI (in total, 1 or 2 mg). Patients’
tolerance, anxiety and sedation were
assessed using a questionnaire and a
visual analogue scale immediately
before and after MRI. Image quality
was evaluated using a five-point-scale.
In TG1, 18/36 MRI examinations
(50%) had to be cancelled, the reduc-
tion of anxiety was insufficient in
12/18 remaining patients (67%). In
TG2, 35/36 MRI examinations (97%)
were completed successfully, without
relevant adverse effects. MRI image
quality was rated higher among pa-
tients of TG2 compared to TG1
(p<0.001). Low-dose intranasal mid-
azolam is an effective and patient-
friendly solution to overcome anxiety
in claustrophobic patients in a broad
spectrum of body MRI. Its anxiolytic
effect is superior to that of the orally
administrated form.
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Introduction
Although the architecture and design of magnets for mag-
netic resonance imaging (MRI) have profoundly changed
over the last few years, staying enclosed in a magnet may
trigger the panic reactions in patients suffering from claus-
trophobia. Hence, the investigation of claustrophobic patients
in a MRI scanner still represents a challenge.
According to the literature, up to 10% of all MRI
examinations cannot be completed, or even started, because
of claustrophobia [1, 2]. Although there are some
alternative techniques to facilitate the MRI of claustro-
phobic patients (e.g. prism eyeglasses, verbal tranquillisa-
tion), medicamentous sedation and anxiolysis remain the
most useful options in order to achieve good examination
results. When medicamentous sedation for MRI is desired,
benzodiazepines are used in most MRI centres. These
medicaments are often administered intravenously or
orally, whereas the latter application is preferred. A
frequently used agent is midazolam, which is approved for
oral, i.v. and intramuscular use in most countries of the
world.
The intranasal use of midazolam has been investigated in
pediatric as well as adult populations [3–8]. Intranasal
application has the following advantages compared to oral
application: absent hepatic first-pass metabolisation, re-
sulting in a faster onset of action and a higher bioavail-
ability (of up to 83%), minor toxicity and improved
controllability due to the missing peak concentration, and a
lesser sedation [4, 8, 9].
F. T. C. Tschirch (*) . K. Göpfert .
G. Brunner . D. Weishaupt
Institute of Diagnostic Radiology,
University Hospital Zürich,
Rämistrasse 100,
CH-8091 Zürich, Switzerland
e-mail: Frank.Tschirch@usz.ch
Tel.: +41-1-2553060
Fax: +41-1-2554506
J. M. Fröhlich
Klus-Apotheke,
Hegibachstrasse 102,
CH-8032 Zürich, Switzerland
In a prospective double-blinded placebo controlled
randomised trial, Hollenhorst et al. [2] have shown a
significant reduction of MRI-related anxiety and improved
MRI image quality in patients who received intranasal
midazolam. In the study of Hollenhorst et al. [2], the dose
of the midazolam was relatively high, and all patients were
scheduled for MRI of the head or the upper body.
The purpose of this study was to assess the potential of a
ready-to-use low-dose (1 mg) midazolam nasal spray
compared to the oral application of midazolam in claus-
trophobic patients undergoing routine MRI in a broad
spectrum of MRI body investigation techniques.
Patients and methods
The study was approved by the local ethics committee and
written informed consent was obtained from all of the
participating patients prior to the examination.
Patients
Patients were only included in the study if they fulfilled the
following criteria: (1) referral for clinical body MRI (i.e.
MRI of the chest, abdomen, pelvis or musculoskeletal
system, including MRI of the spine) or referral for MRI
angiography of the thoracic, abdominal or pelvic vessels,
as well as of the peripheral arteries; (2) necessity to perform
a medicamentous sedation prior to MRI, based on the
request of the patient or the referring physician due to
claustrophobia of the patient. Exclusion criteria were: age
<18 years, general contraindications for MRI (i.e. cardiac
pacemakers, neurostimulators, ferromagnetic implants
etc.), pregnancy, drug or ethanol abuse, breast feeding,
general contraindications for the use of midazolam (i.e.
myasthenia gravis, known reverse or allergic reactions
etc.), participation in another study simultaneously, and the
presence of otorhinolaryngeal diseases (e.g. status post-
surgery, rhinitis, nasal polyposis).
For this study, a total of 72 consecutive adult patients (42
females, 30 males, mean age 52.7 years; total of 72
scheduled examinations) were included. These patients
were randomly assigned to one of two treatment groups
(TG) according to a randomisation list. Patients in TG1
received 7.5 mg midazolam orally (Dormicum, Roche
Pharma AG, Reinach, Switzerland) 15 min before MRI.
Patients of TG2 received one pump corresponding to
0.1 ml of a ready-to-use nasal spray containing a 0.5%
midazolam solution into each nostril immediately prior to
MRI (in total, 1 mg midazolam). If the dose of one pump
per nostril was not sufficient in order to perform MRI, the
intranasal administered dose could be increased to up to
two pumps per nostril (total of 2 mg midazolam). The
decision on whether a second intranasal dose of midazolam
had to be applicated was made by the attending radiologist.
The intranasal midazolam formulation was developed
especially for this purpose according to the NRF
recommendations (Neues Rezeptar Formularium, ABDA
Bundesvereinigung Deutscher Apothekerverbände, D-
65760 Eschborn, Govi-Verlag Pharmazeutischer Verlag
GmbH, 1999) and manufactured by a pharmacist (J.M.F.).
The ready-to-use nose spray in the off-label use contained
3 ml of the injectable aqueous 0.5% Dormicum solution
(Roche Pharma AG, Switzerland) with 0.5 mg midazolam
(0.1 ml) per single dose. For conservation, 10 mg/ml
benzyl alcohol were added. The solution was filtered
through a 0.22-μm sterile filter (OptiScale, Millipore
Corporate, Billerica, MA, USA) and prepared under
aseptic conditions in order to reduce, as far as possible,
any bacterial contamination and possible glass splinters
resulting from the opening of the glass ampoules. The
device for application of the nose spray consisted of a
10-ml bottle with a microdoseur nose adapter (Pharminno-
va, Waregem, Belgium) screwed on top of it, allowing a
reproducible and standardised dosing of 0.1 ml (Fig. 1). In
order to exclude the administration of air, it was important
to use this type of device in an upright position of the
patient after having checked the complete filling of the
tubes and pump system by spraying once into the air
(Fig. 2).
Monitoring of patients during MRI
Each patient received a venous cannulation before the
application of midazolam for safety reasons in order to
assure venous access in case of adverse effects. The
antagonist flumazenil (Anexate, Roche Pharma AG,
Switzerland) was available at any time. For safety reasons,
Fig. 1 Photograph of the
used ready-to-use nasal spray
for the midazolam application.
The device for application of the
ready-to-use nasal spray con-
sisted of a 10-ml bottle with a
microdoseur nose adapter
screwed on top of it, allowing
a reproducible and standardised
dosing of 0.5 mg per pump
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all patients were warned to not drive a vehicle or to operate
machinery 24 hours after the application of midazolam.
During MRI, patients were in permanent contact with the
investigating technician by means of headsets and a
microphone. Heart rate and respiratory frequency were
surveyed during the whole examination. Additionally, the
patient received an emergency ball to disrupt the exami-
nation if necessary.
MRI
MRI was performed on one of two 1.5-T scanners (Signa
EchoSpeed Plus, Signa TwinSpeed Plus; GE HealthCare,
WI, USA) according to the corresponding examination
protocol (Table 1). All MRI protocols were standardised
and consisted of various sequences without and with a
contrast agent. The number of coils as well as the patients’
position were selected depending on the investigated body
region. If necessary (particularly concerning abdominal
and thoracic MRI), special examination techniques were
used, such as respiratory triggering and breath-holding
techniques.
Data analysis
Feasibility of the study
In both TGs, the examination was classified as “feasible” or
“non-feasible.” The study was categorised as “feasible” if
all of the planned MRI sequences could be accomplished.
If one or more MRI sequences of the corresponding
protocol could not be performed, the study was rated as
“not-feasible” and the reason for the termination of the
examination was noted.
Anxiety, sedation and adverse effects
The efficiency of midazolam in both TGs was assessed by
the patients themselves, as well as by the technician who
performed the MRI examination. Patients’ anxiety before
the examination, as well as the experienced fear during the
investigation, was evaluated by a visual analogue scale
(VAS) immediately before and 15 min after MRI. The VAS
was presented as a line of defined length (commonly,
100 mm) with anchors at either end. The patients were
instructed to grade their fear sensation by placing a mark
between the two anchors, without being told the precise
distance between them. The left anchor was defined as the
absence of fear, the right anchor was defined as maximal
fear. The distance of one of the anchors and the patient’s
Fig. 2 Photograph shows how
the ready-to-use nasal spray was
administered. In order to ex-
clude the administration of air, it
is important to use this type of
device with the patient being in
an upright position
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mark was expressed in millimetres of the maximum of fear
(100 mm). A reduction of the anxiety on the VAS below
50% was categorised as “not sufficient,” and over 70% was
categorised as “sufficient.” Values in between were
described as “non-classifiable.” In addition, all patients
received two questionnaires. One of these questionnaires
was filled out at our institution about 15 min after MRI.
The patients were asked if they had faced problems during
the examination (e.g. recurrent fear sensations), of what
kind these problems had been and if they had experienced
any adverse effects by the use of the midazolam spray
(such as nasal burning sensation, pain etc.). Additionally,
the patients had to answer the question as to whether they
would repeat the examination. Finally, the patients were
asked to fill out a second questionnaire at least five days
after MRI and to send it back to our institution. In this
second questionnaire, the patients could note for how long
their attention was reduced, whether problems or adverse
effects arose after leaving the radiology department and,
again, whether they would repeat the MRI procedure. The
technician who performed MRI was also asked to fill out a
standardised questionnaire for each patient. This question-
naire contained several questions concerning the patient’s
cooperation and a subjective impression of the degree of
anxiety or sedation of the patient during the examination.
MRI image quality
Image quality among the patients of TG1 and TG2 was
rated by a single radiologist (D.W.) with 10-years of
experience in body MRI. The reader was blinded
concerning the application form of midazolam (oral versus
intranasal). MRI image quality of each MRI examination
was assessed using the following five-grade scale: grade 0,
very poor image quality; grade 1, poor image quality; grade
2, satisfactory image quality; grade 3, good image quality,
and grade 4, excellent image quality. Grade 0 or 1 was
applied if the examination was of no or very little
diagnostic usefulness because of extensive motion artifacts
that were not caused by pulsation or normal peristalsis.
Examinations classified as grade 2 allowed us to make the
diagnosis, but some motion artifacts were still present.
Examinations graded as 3 and 4 included a good or
excellent image quality, with no or almost absent motion
artifacts.
Statistics
Statistical analysis was performed by SPSS 12.0.1 for
Windows (SPSS Inc.; Chicago, IL, USA). Statistical
significance was accepted if p<0.05. For MRI image
quality, the Chi-square test was used. The values of the
VAS in both TGs were compared by means of the Mann-
Whitney test. Analysis of the questionnaire concerning the
willingness to repeat the MRI examination was made by
Fisher’s exact test.
Results
Seventy-two patients were scheduled for a total of 72 MRI
examinations (Table 1). There were no statistically signif-
Table 1 Overview of the per-
formed magnetic resonance im-
aging (MRI) protocols
TG=treatment group; SD=stan-
dard deviation; 1=number of
examinations; 2=nine examina-
tions in TG1 could not be
started due to claustrophobia
MRI protocol TG1 TG2
n1 Mean scanning time (min) n1 Mean scanning time (min)
Neck 2 43 2 30
Thorax Thoracic outlet 2 33 2 43
Abdomen Liver 3 48 5 52
Pancreas 1 45 1 45
Kidney/adrenals 1 40 1 45
Defecography 0 – 1 20
Pelvis 4 32 5 45
Spine Cervical 2 28 2 28
Thoraic 1 30 0 –
Lumbar 3 28 3 34
Lumbar incl. sacroiliac joints 0 – 2 35
Extremity Shoulder 2 42 4 41
Forearm 1 15 1 25
Knee 2 40 1 30
Forefoot 1 45 2 40
MRA Thoracic 1 40 1 35
Abdominal 1 30 2 38
Pelvic/femoral 0 – 1 40
Total/mean (+/−SD) 272 36.0(+/−16.8) 36 39.4(+/−15.5)
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icant differences between both TGs with regards to the
examined body regions and examination techniques
[examinations with respiratory triggering: 8 (TG1)/10
(TG2); examinations with breath-hold technique: 11
(TG1)/13 (TG2)]. There were also no statistically signif-
icant differences with regards to gender, age and weight of
the patients (female/male ratio in TG1 19/17, in TG2 23/13;
mean age +/−SD in TG1 51.8 years +/−10.9, in TG2
53.6 years +/−12.6; mean weight +/−SD in TG1 81 kg +/
−12.9, in TG2 75 kg +/−17.8).
Feasibility of the study
After oral application of midazolam, MRI had to be
cancelled in 9/36 examinations (25%) due to patients
reasons. MRI could not be started in another nine patients
(25%) due to insufficient sedation of the patient, resulting
in 18/36 non-diagnostic studies (50%). There were no
cancellations of MRI after the application of intranasal
midazolam. Only one patient (2.8%) in TG2 had a non-
diagnostic examination, since he could not cooperate due
to amblyacousia (Fig. 3).
Vital signs and adverse effects
There were no significant changes in the heart rate or
respiratory frequency before, during and after the exami-
nation in either TG. The antagonist flumazenil (Anexate,
Roche Pharma AG, Switzerland) was not needed in any
case. No patient required special monitoring or treatment
after the examination. Apart from a temporary nasal
burning sensation in 61.1% (22/36 patients) of the patients
of TG2, there were no relevant adverse effects in both TGs.
Anxiety and degree of sedation
The evaluation of the VAS for the reduction of the pain
experienced resulted in a highly significant difference
between the two TGs (p<0.001). In TG1, the reduction of
anxiety was rated as not sufficient (i.e. a decrease of the
anxiety as assessed on the VAS below 50%) by 30/36
patients (83.3%), whereas the patients of TG2 showed a
sufficient reduction of anxiety (i.e. a decrease of the anxiety
as assessed on the VAS over 70%) in 35/36 patients
(97.2%) (Fig. 3). The dose of 1 mg in TG2 was sufficient in
31 patients, whereas the dose had to be repeated during the
examination (total dose of 2 mg) in five patients (13.9%).
According to the questionnaires which were filled out
directly following MRI, 18/36 (50%) patients of TG1
would repeat the examination, 3/36 patients would not
repeat the examination and 15/36 patients did not mark an
answer. Twenty of thirty-six (20/36) patients of TG2 would
repeat the examination and 3/36 patients denied to a repeat
of the examination or to undergoMRI in future. Concerning
the questionnaires which were filled out by patients at
home, we only received 11/36 (30.6%) letters from patients
after spray application, as well as 6/36 (16.7%) letters from
patients after the oral application of midazolam. Therefore,
no statistical evaluation was possible. All 11 patients who
received the midazolam spray and who had sent back the
questionnaire reported that they would repeat the investiga-
tion (100%), whereas only 3/6 patients of TG1 (50%)
returning the questionnaires would repeat the MRI proce-
Fig. 3 Diagram illustrating the
number of patients in both
treatment groups (TGs) with a
feasible MRI examination, suf-
ficient anxiety reduction (>70%
measured by visual analogue
scale, VAS) and satisfactory to
excellent MRI image quality
(grades 2 to 4)
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dure. The duration of attention restriction was stated with a
high variability by the patients. The data varied between 0
and 120 min (mean 19.8 min) after intranasal application
and 15 to 120 min (mean 67.5 min) after oral medication.
These values did not differ statistically significantly
(p=0.275). The technician’s impression about patient
anxiety and cooperation during MRI was significantly
better in TG2 versus TG1 (p<0.001). In 34/36 examinations
(94.4%) of TG2, the technician had a positive impression,
whereas in TG1, the technician’s impression was only
positive in 9/36 examinations (25.0%).
MRI image quality
In contrast to oral application (12/36), the image quality
after intranasal application of only 1 mg midazolam was
satisfactory to excellent in most MRI examinations (31/36),
independent from respiratory triggering, as well as breath-
hold techniques (Fig. 3). Statistical evaluation of the image
quality resulted in a highly significant difference in favour
of TG2 (p<0.001).
Discussion
Conscious sedation is one of the most important measures
to help claustrophobic patients to cope with MRI exam-
ination. The term “conscious sedation” means that the
patient is able to maintain his/her airway and respond
appropriately to physical stimulation and verbal commands
while sedated [10]. For this purpose, midazolam is often
used because its pharmacological properties are superior to
other benzodiazepines (fast onset, better tissue compatibil-
ity, controllability of effect, short duration of action of 20 to
40 min, short elimination half-time of 1.5 to 3 h).
Additionally, anxiolysis appears already at a low dosage
and, usually, there are no relevant adverse effects, apart
from a slight sedation [3].
Midazolam may be administrated orally, intravenously,
intrarectally or intranasally. For radiological examinations,
in particular, to achieve conscious sedation in claustro-
phobic patients referred for MRI, midazolam is generally
administrated via the oral or the i.v. route in most
institutions. The advantage of oral administration com-
pared to i.v. administration is the fact that it does not
present an invasive procedure and most radiologists feel
more comfortable with oral use than with i.v. use. On the
other hand, i.v. use compared to oral application offers the
advantage that there is no hepatic first-pass metabolism,
resulting in a faster onset of action and a higher bioavail-
ability of the drug. In addition, i.v. administration is not
influenced by the bowel contents and movement, resulting
in an improved controllability [11, 12].
In the present clinical trial, we compared 7.5-mg
midazolam tablets with intranasal low-dose application.
This oral dose has been described to offer a favourable
relationship between desirable and undesirable effects [13].
The inferior result of the oral application regarding
feasibility of the examinations, reduction of anxiety and
image quality might be explained by the study of Biro et al.
[13]. Biro et al. [13] found a marked interindividual
variability of sedation and amnesia after orally adminis-
tered midazolam prior to surgery. Additionally, anxiolysis
was lacking in all orally administered doses, showing no
difference compared to the placebo group, whereas seda-
tion and amnesia were dose-dependent.
The intranasal application of midazolam is well known
in paediatric medicine, especially for painful procedures
such as dental interventions, treatment of acute seizures, for
premedication and trauma management [5, 6]. In adults, the
intranasal application of midazolam has been reported for
sedation during upper gastrointestinal endoscopy, for
premedication, as well as for the treatment of panic
disorders [3, 7, 8]. However, the experience with
midazolam in patients for radiological examinations and,
in particular, in patients referred for MRI is limited. Several
years ago, Moss et al. [14] presented their preliminary
results using intranasal midazolam for claustrophobic MRI
patients. This route of administration reduced the necessity
for i.v. sedation from 67% to 17%. Recently, Hollenhorst et
al. [2] showed, in a double-blind placebo controlled study,
that intranasally applicated midazolam leads to a signifi-
cant reduction in MRI-related anxiety, resulting in an
improved MRI image quality. In the study of Hollenhorst et
al. [2], 54 consecutive patients scheduled for MRI of the
head were divided into two groups receiving either 4 mg of
midazolam intranasally or a placebo intranasally. No
cancellation of MRI occurred in the midazolam group
consisting of 27 patients, whereas 4/27 (14.8%) patients
receiving the placebo panicked and terminated MRI earlier.
Our study differs from that of Hollenhorst et al. [2] in many
respects. In contrast to Hollenhorst et al. [2], we only
administered 1 mg of midazolam intranasally in the
majority of cases. The effectiveness of the relatively low
dose of 1 mg of midazolam is known from other
applications. Schweizer et al. [3] reported an improvement
of panic disorders in 4/5 patients using a total dose of 0.5–
1.0 mg of self-administrated intranasal midazolam drops.
Moss et al. [14] also used a total dose of 0.5–1.0 mg in
claustrophobic patients scheduled for MRI, reducing
dramatically the number of patients needing additional i.v.
sedation. Another difference to the study of Hollenhorst et
al. [2] is the time delay between the application of the drug
and the start of MRI. In their study, intranasal application of
midazolam took place 15 min before MRI. In the study of
Moss et al. [14], patients received two drops per nostril of a
midazolam solution (total 0.5 mg) prior to entering the
scanner without a time definition. This dose could be
repeated during the MRI procedures (total 1.0 mg).
In our study, we administered the intranasal spray just
before MRI. According to the literature, the effect of the
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intranasally applicated midazolam starts in less than 5 min
[10]. In a clinical setting, it is easier to administer the
intranasal spray on the MRI table if the patient is
complaining of claustrophobia. Moreover, one main
difference compared to the study of Hollenhorst et al. [2]
is that our patients were scheduled for body MRI and not
for a neuroradiological indication. In the study of Moss et
al. [14], the kind of examined body regions was not
reported. Compared to neuroradiological MRI, body MRI
is usually more time consuming and partially requires
particular techniques which need the compliance and active
cooperation of the patient.
The excellent effect of the intranasally used low-dose
midazolam may be explained by the following reasons. In
contrast to oral and rectal administration, intranasal
midazolam administration has no first-pass effect in the
liver and no interference with the bowel contents. There-
fore, the interindividual differences in the dose-related
effects are much smaller. Using a nasal spray absorption
through the nasal mucosa is fast and virtually complete
(about 83%), resulting in a quite easily controllable
midazolam application [15]. The fast and intense effect
of the small and amphiphilic midazolam molecule may be
explained by the supposed predominant fast paracellular
transport through the nasal mucosa, as well as the easy
passage through the blood–brain barrier [16, 17]. Accord-
ing to the literature, the intranasal spray is also superior to
nose drops, which are partially swallowed [2, 8, 13];
compared to i.v. administration, there is a lower toxicity
due to decreased peak concentration and its usage is easier
and less painful [2, 15].
Although intranasal application is an off-label use and
not yet approved by the authorities, it seems to be safe. As
also described by other authors, there were no major
adverse effects requiring further therapy, only a local
temporary burning sensation after intranasal spray applica-
tion was detected in 61.1% (22/36) of patients [2, 14]. This
is probably due to the used preserving agent (benzyl
alcohol) and the low pH value (3.3) of the aqueous
midazolam solution [15]. Before starting a broad clinical
use of the low-dose intranasal application, further efforts
should be made to eliminate this burning sensation, by
using another preserving agent for example. Additionally, a
spray form applicable in a lying position is desirable, as
MRI patients often are lying on the examination table when
mentioning claustrophobia. This could be the subject of
future investigations.
We acknowledge the following limitations. In this study,
we only used a VAS to quantify the severity of claustro-
phobia before and after MRI; no psychometric test was
made, especially no Spielberger State-Trait Anxiety In-
ventory (STAI). The reason for this is that Dantendorfer et
al. [18] could not find a correlation between the values of
STAI and the presence of motion artifacts. They assumed
that STAI is not able to measure the “special fear” caused
by the MRI scanner. Probably, the VAS just before and
after MRI represents more accurately the reality. On the
other hand, Hollenhorst et al. [2] found similar results using
both STAI and VAS. Hence, it may be concluded that the
VAS is probably sufficient to assess the grade of anxiety.
Other investigators also worked successfully using only the
VAS [13]. Additionally, the time delay of 15 min between
the oral administration of midazolam and MRI could be too
short, possibly leading to the bad results in TG1. In other
studies, a longer time interval (e.g. 60 min) has been used
[13].
In conclusion, the intranasal application of low-dose
midazolam immediately before MRI is an effective and
patient-friendly solution to overcome anxiety in claustro-
phobic patients and results in a good image quality and a
higher rate of feasible examinations.
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